ms-553
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02406989)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Diabetes Mellitus, Type 1 · Phase 1
- Diabetes Mellitus, Type 2 · Phase 1
- Diabetic Retinopathy · Phase 1
- Healthy Volunteers · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Lymphoid · Phase 1/Phase 2
- Lymphoma, B-Cell · Phase 1/Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 1/Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1/Phase 2
- Macular Edema · Phase 1
Mechanism of action
- Protein kinase C betaINHIBITOR
PRKCB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ms-553
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06979076 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2026 | MingSight Pharmaceuticals Pty Limited |
| NCT05720052 | Phase 1/Phase 2 (Phase 2) | Feb 6, 2023 | MingSight Pharmaceuticals Pty Limited |
| NCT05272813 | Phase 1/Phase 2 (Phase 2) | Apr 28, 2022 | MingSight-Relin Pharmaceuticals Co., Ltd. |
| NCT04187443 | Phase 1 | Mar 4, 2020 | Fountain Medical Development Co., Ltd., MingSight-Relin Pharmaceuticals Co., Ltd. |
| NCT02406989 | Phase 1 | Apr 1, 2015 | MingSight Pharmaceuticals Pty Limited |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MingSight Pharmaceuticals Pty Limited | For profit | 3 | 3 | 2 | 2015 |
| MingSight-Relin Pharmaceuticals Co., Ltd. | For profit | 2 | 2 | 2 | 2020 |
| Fountain Medical Development Co., Ltd. | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1